UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close

This is embarrasing..

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing..

An error occurred while processing the form. Please try again in a few minutes.

CLSI I/LA35

Newborn Screening for Cystic Fibrosis; Approved Guideline

active, Most Current
Buy Now
Organization: CLSI
Publication Date: 1 November 2011
Status: active
Page Count: 80
scope:

This guideline describes the use of newborn screening (NBS) laboratory tests for detecting risk for cystic fibrosis (CF) from newborn dried blood spots (DBS). It addresses both the primary screening tests and the second or third tier tests performed on DBS. The guideline presents the various approaches used for CF NBS and discusses their strengths and limitations. It addresses the detection of specific cystic fibrosis transmembrane conductance regulator (CFTR) mutations in second-tier screening with the immunoreactive trypsinogen/deoxyribonucleic acid (IRT/DNA) strategy.

Emphasis is placed on the selection of CFTR panels that have the potential to optimize IRT/DNA sensitivity and potentially ensure equity in NBS, ie, equal detection of CF in "minority populations" to the extent possible at this time. The guideline focuses on NBS and excludes prenatal testing. Only mutations currently known to cause CF disease are included in these recommendations. Special attention is given to geographically and ethnically diverse populations. The document development committee recognizes that the effects of additional mutations not listed, or even combinations of those present, are not fully understood and should be interpreted with utmost caution.

The intended target audience includes NBS laboratory and program personnel, regulatory agencies, CF center personnel, neonatologists, primary care providers (PCPs), organizations responsible for networks of CF centers, and a variety of public health policy makers.

Document History

CLSI I/LA35
November 1, 2011
Newborn Screening for Cystic Fibrosis; Approved Guideline
This guideline describes the use of newborn screening (NBS) laboratory tests for detecting risk for cystic fibrosis (CF) from newborn dried blood spots (DBS). It addresses both the primary screening...

References

Advertisement